- Home
- PDD vs BMY Comparison
PDD vs BMY Comparison
Compare PDD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | BMY |
|---|---|---|
| Founded | 2015 | 1887 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.5B | 113.5B |
| IPO Year | 2018 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PDD | BMY |
|---|---|---|
| Price | $87.07 | $67.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $139.22 | $61.73 |
| AVG Volume (30 Days) | 5.7M | ★ 11.9M |
| Earning Date | 05-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $48,194,000,000.00 |
| Revenue This Year | $15.35 | N/A |
| Revenue Next Year | $12.63 | N/A |
| P/E Ratio | ★ $10.63 | $22.87 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $71.94 | $42.52 |
| 52 Week High | $139.41 | $68.64 |
Technical Indicators
Market Signals| Indicator | PDD | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 63.48 |
| Support Level | $82.60 | $56.46 |
| Resistance Level | $87.76 | $68.10 |
| Average True Range (ATR) | 2.32 | 1.51 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 39.15 | 72.52 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.